Patritumab Deruxtecan Demonstrated Statistically Significant PFS Improvement vs Chemo in Locally Advanced or Metastatic EGFRm NSCLC in HERTHENA-Lung02 Ph 3 Trial September 24, 2024
RYBREVANT® (amivantamab-vmjw) + SOC approved in the US to cut risk of disease progression by more than half in 2L EGFR-mutated advanced NSCLC September 24, 2024
GlyTherix to Partner with SHINE Technologies for Advancing Targeted Radiotherapy in Aggressive Cancers September 24, 2024
Deltacel-01 Advanced Into Expansion Phase Following Safety Monitoring Committee’s Unanimous Recommendation September 24, 2024
FAILED TRIAL: Datopotamab deruxtecan did not achieve statistical significance for OS vs chemo in patients with metastatic HR+, HER2-low or neg breast cancer in TROPION-Breast01 Ph 3 trial September 24, 2024
Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer September 24, 2024
FDA Approves KEYTRUDA + Pemetrexed + Chemo as 1L Treatment for Adult Patients With Unresectable Advanced/Metastatic Malignant Pleural Mesothelioma (MPM) September 24, 2024
TIL-based cNeT program to be discontinued and Ph 1/2a CHIRON and THETIS clinical trials to be closed September 24, 2024
Ph 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study Announced September 24, 2024
Favorable Results Reported for BRACELET-1 Breast Cancer Study Reinforcing Path to Funding of a Registration-Enabling Study September 24, 2024
Positive Preliminary Data Reported in Ph 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer September 24, 2024
Neoadjuvant TAR-200 + cetrelimab nearly doubles the pCRR compared to cetrelimab alone in patients with MIBC September 24, 2024
Blenrep (belantamab mafodotin) combinations in R/R multiple myeloma accepted for regulatory review in Japan September 24, 2024
Blenrep (belantamab mafodotin) combination receives Breakthrough Therapy Designation in China in R/R multiple myeloma September 24, 2024
FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in 1L AML for Patients Unfit for Induction Chemotherapy Treatment September 24, 2024
IND Submission to US FDA for Pilot Study of Pidnarulex Pharmacodynamics in Patients with Advanced Solid Tumors sponsored by NCI September 24, 2024
FDA-Authorized Expanded Access Policy for Metastatic Breast Cancer Patients Announced September 24, 2024
FDA Approves IDE to Initiate Multi-Center Investigator-Initiated Study of Alpha DaRT® in Immunocompromised Patients with Recurrent cSCC September 24, 2024
DARZALEX® (daratumumab)-based quadruplet regimen receives positive CHMP opinion for transplant-eligible patients with newly diagnosed multiple myeloma September 24, 2024
Positive EU CHMP Opinions for KEYTRUDA Regimens as Treatment for Patients With cervical cancer and endometrial carcinoma September 24, 2024
